Clarivate Plc

Clarivate Plc engages in the provision of global information, analytics and workflow solutions. It operates through the Science and Intellectual Property segments. The Science segment is composed of the academia and government, and life science and healthcare product lines. The Intellectual Property segment includes the patent, trademark, domain, and IP management product lines. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clarivate Plc reports strong Q4 earnings, eyes growth opportunities

Clarivate Plc delivered strong financial results in Q4 2022, driven by the successful ProQuest acquisition and solid organic growth across segments. The company is focused on achieving higher organic growth, reducing leverage, and leveraging culture for success.
While facing macroeconomic challenges and pricing pressures, Clarivate Plc is confident in its strategic plans and capital structure initiatives. Opportunities lie in leveraging AI, enhancing product offerings, and capitalizing on the positive pricing environment.
Navigating challenges such as tough comps, managing inflation impact, and balancing quarterly patterns will be crucial. The company's proactive approach to growth, focus on customer value, and upcoming Investor Day position it well for future success.

Clarivate Plc reports stable Q1 performance amidst growth challenges

Clarivate Plc's Q1 2023 performance showcased stable revenue, strong margins, and strategic financial initiatives despite challenges in net income and organic growth cadence.
The company's strengths lie in market engagement, AI innovation, maintained outlook, and effective pricing strategies, positioning it for continued growth.
Challenges include earnings volatility, execution hurdles in growth projections, and longer-term segment revenue impacts, necessitating strategic planning and operational focus.
Opportunities in AI applications, cash flow utilization, revenue drivers, and segment progress offer avenues for revenue diversification, growth investments, and market expansion.

Clarivate Plc faces revenue challenges but drives growth through innovation

Clarivate Plc's Q2 performance saw challenges in key segments impacting revenue and outlook, despite operational improvements and strategic initiatives.
While facing hurdles in patent annuities and commercialization subsegment growth, the company focuses on sustainability, product innovations, and customer-centric strategies for future growth.
Detailed financial results and revised guidance reflect the company's proactive approach to address challenges and capitalize on opportunities for sustainable growth.
With a pivot around three segments and emphasis on higher-touch sales, Clarivate aims to navigate challenges, leverage opportunities, and drive revenue growth in the evolving market landscape.

Clarivate Plc reports Q3 growth, tackles challenges, eyes tech acquisitions

Clarivate Plc's Q3 performance showed growth in key segments despite challenges in IP and LS&H businesses.
Opportunities lie in technology acquisitions, analytic platforms, and direct sales to pharma companies.
Management remains optimistic about quarterly results and progress, focusing on enhancing growth strategies.

Clarivate Plc reports solid Q4 performance amidst sector challenges

Clarivate Plc's Q4 2023 performance reflects progress in key segments and a strategic focus on organic growth and operational efficiencies.
While facing challenges in the A&G segment and market conservatism, the company is leveraging strengths in Life Sciences investments and pricing strategies.
Opportunities lie in growth acceleration through new offerings, improved organic growth, and renewed optimism in the life sciences sector.

Clarivate Plc reports Q1 revenue growth, eyes segment expansion

Clarivate Plc's Q1 performance showed promising organic revenue growth and steady renewal rates, with a focus on future investments for growth.
While facing financial challenges and neutral market conditions, the company sees opportunities in segment growth and real-world data solutions.
Overall, Clarivate remains on track with full-year guidance, aiming for 1% organic growth and focusing on driving subscription business growth.

Clarivate Plc reports mixed Q2 results, focuses on growth strategies

Clarivate Plc reported mixed financial results in Q2 2024, with slight revenue growth but challenges in certain segments.
Management emphasized resilience in adjusted EPS and operating cash flow, focusing on growth plans and operational improvements.
Analysts raised concerns about project delays and segment performance, but opportunities in product innovation and revenue growth were highlighted.
The company aims to drive subscription revenue growth through upcoming product releases and investment in business.

Clarivate Plc faces revenue decline in Q3 but focuses on growth strategies

Clarivate Plc's Q3 2024 earnings call highlighted challenges in revenue decline and net loss, with a focus on repositioning and value creation. The company is implementing a Value Creation Plan to optimize its business model and drive sustainable growth. Opportunities exist in improving sales execution, product innovation, and aligning the portfolio for enhanced profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.

LONDON , May 29, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today announced that the Company will present at the following investor conferences in June 2024: Jonathan Gear, Chief Executive Officer, will present at the William Blair Growth Stock Conference on Tuesday, June 4, 2024, at 2:00 p.m. Central Time (3:00 p.m.

Clarivate to Present at Upcoming Investor Conferences in June 2024

New report highlights innovations poised to drive significant clinical and market impact LONDON , May 22, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of the Medical Technologies to Watch in 2024 report. This first installment of a two-part series offers a comprehensive predictive analysis of high-growth medical technology markets poised to generate over $1 billion in value or achieve double-digit growth within the next five years.

Clarivate Identifies Five Breakthrough Medical Technologies Set to Transform Patient Care in 2024

Analyzing six of the key trademark registers from around the world LONDON , May 21, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released the Trademark Filing and Litigation Trends 2024 Report, analyzing six of the key trademark registers from around the world: the United States (U.S.), the European Union (EU), the United Kingdom (U.K.), Mainland China, Japan, and South Korea. The report reveals that trademark filing activity worldwide saw a return to stability and growth in 2023 after three years of market volatility, indicating solid growth in 2024.

New Clarivate Report Indicates Solid Growth in 2024 Global Trademark Filing Activity

Providing faster and more accurate answers to critical business questions LONDON , May 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, launched the first publicly available version of Trademark Watch Analyzer today at the 2024 International Trademark Association Annual Meeting. As the next-generation trademark protection solution enhanced by artificial intelligence (AI) and cloud technology, this solution combines Clarivate global trademark and case law data, in-house IP expertise, and cutting-edge AI technology.

Clarivate Launches AI-Enhanced Solution to Accelerate Trademark Watching

Infringement declined globally from 2012 to 2019 LONDON , May 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released the 2024 Non-Practicing Entity Global Litigation (NPE) Report to analyze NPE enforcement activities and their patent validity challenges across the globe. The report revealed that the United States, Germany and Mainland China are the three countries and regions with the most infringement cases filed by NPEs.

New Clarivate Report Reveals that the U.S., Germany and Mainland China have the most Non-Practicing Entity Litigation

IP solution maximizes operational efficiency for leading automation company LONDON , May 9, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that OMRON has selected IPfolio™, an intellectual property management software from Clarivate to transform their IP operations. This solution will enable OMRON, a leading automation company to make smarter decisions and plan strategically using IP data and analytical insights.

OMRON Selects IPfolio from Clarivate

While the top- and bottom-line numbers for Clarivate (CLVT) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Clarivate (CLVT) Q1 Earnings: A Look at Key Metrics

Clarivate PLC (CLVT) came out with quarterly earnings of $0.14 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.18 per share a year ago.

Clarivate PLC (CLVT) Q1 Earnings Meet Estimates

— Reaffirms 2024 Outlook — LONDON , May 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2024. First  Quarter 2024 Financial Highlights Revenues of $621.2 million decreased 1.3% Organic revenues decreased 1.7%, as an increase in subscription revenues of 2.4% was more than offset by a decrease in transactional and other revenues of 11.4% and re-occurring revenues of 5.1% Net loss attributable to ordinary shares of $93.8 million; Net loss per diluted share of $0.14 Adjusted net income(1) of $103.5 million decreased 20.9%; Adjusted diluted EPS(1) of $0.14 decreased 22.2% or $0.04 Adjusted EBITDA(1) of $236.3 million decreased 6.5%; Adjusted EBITDA margin(1) of 38.0% decreased 220 basis points primarily due to lower revenues Net cash provided by operating activities of $176.2 million decreased $51.3 million; Free cash flow(1) of $111.8 million decreased $56.4 million primarily due to the timing of working capital "We are making great progress this year on key objectives including product investments and operational initiatives to drive future organic revenue growth," said Jonathan Gear, Chief Executive Officer.

Clarivate Reports First Quarter 2024 Results

Empowering  biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis LONDON , May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions.

Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis

Enhancements enable pharma, biotech and generics companies to streamline regulatory tracking and optimize life cycle management for small molecules and biologics  LONDON , May 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking.

Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success

LONDON , May 1, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT; CLVT PR A) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024. On the mandatory conversion date, which is scheduled to occur on June 3, 2024, each Preferred Share will automatically and mandatorily convert into a number of ordinary shares of Clarivate (and cash in lieu of any fractional ordinary shares) based on the average volume weighted average price ("VWAP") of Clarivate's ordinary shares over a 30-trading day period that begins on, and includes, April 18, 2024 and is scheduled to end on, and include, May 30, 2024 (the "valuation period").

Clarivate Declares Dividend on Mandatory Convertible Preferred Shares

Clarivate (CLVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clarivate PLC (CLVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Three-part report investigates rapid pipeline growth, partnerships, clinical trials ,  and patient access challenges in cancer treatment LONDON , April 30, 2024 /PRNewswire/ -- BioWorld™ published by  Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, explores the growing investment in CAR T therapy development in mainland China in a new series titled " China's CAR T market comes of age." The report examines the dynamic realm of CAR T-cell therapies in China, including the rapid pipeline growth, deals, clinical trials and challenging issues surrounding patient access to very expensive and effective cancer therapeutics.

BioWorld by Clarivate Explores the Future of CAR T Therapy in Mainland China in Special Report

LONDON , April 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announces it has signed the United Nations Sustainable Development Goals (UN SDGs) Publishers Compact. Signatories of the compact pledge to develop sustainable practices and act as champions of the SDGs during the Decade of Action (2020-2030).

Clarivate joins United Nations SDG Publishers Compact

Acquisition supports critical client workflow and reporting needs with proprietary SaaS platform, automating regulatory report authoring and compliance across manufacturing operations, supply chain and quality management LONDON , April 23, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced that it has acquired Global QMS, Inc., known as Global Q, a provider of cloud-based solutions that enable life sciences clients to automate regulatory reporting and compliance management. Financial terms of the transaction were not disclosed.

Clarivate Acquires Global QMS, Inc., Expanding Life Sciences & Healthcare Segment into New Markets

New solution offers comprehensive tracking and analysis of market share and size in Brazil, Colombia, Argentina, Chile, Peru and Ecuador LONDON , April 17, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released its LatAm market tracking solution, in collaboration with Global Healthcare Intelligence, a leading provider of market intelligence on healthcare infrastructure in frontier markets. The new solution is the next phase of an expanding partnership between Clarivate and Global Healthcare Intelligence, enabling in-depth and actionable analysis of the medical device market in Latin America (LatAm).

Clarivate Launches LatAm Market Tracking Solution in Partnership with Global Healthcare Intelligence Enabling Real-Time Tracking of Medical Device Markets

Clarivate (CLVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Clarivate (CLVT) Beat Estimates Again in Its Next Earnings Report?

LONDON , April 15, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the first quarter before the market opens on Wednesday, May 8, 2024. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com.

Clarivate to Report First Quarter 2024 Results on May 8, 2024

--- Clarivate CFO and Segment Presidents Discuss Growth Initiatives Including Generative AI Strategies --- LONDON , April 1, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that in conjunction with the recent launch of Clarivate in the Age of AI video webinar presentations, the Company's Chief Financial Officer and its three segment Presidents participated in panel discussions at investor conferences in March 2024. The recordings, which cover various topics including how Clarivate is leveraging content and solutions, incorporating Generative AI strategies and investing to realize its long-term growth potential, can be accessed as follows: March 7: Oppenheimer Capital Markets Tech and Analytics Virtual Bus Tour.

Clarivate Leadership Presents at Recent Investor Conferences

Acquisition of MotionHall reinforces strategy to lead market-specific solutions, including workflows and expert services fuelled by industry vertical AI LONDON , March 21, 2024 /PRNewswire/ --  Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, has announced an agreement to acquire the substantial majority of assets of MotionHall, a Silicon Valley technology start-up company serving the life sciences with industry vertical artificial intelligence (AI) solutions. The asset purchase serves as a key component of the Clarivate™ Life Sciences & Healthcare strategy to deliver transformative intelligence through the application of generative AI (GenAI) and proprietary industry vertical AI solutions.

Clarivate Acquires AI Start Up to Accelerate Strategy and Business Development Success for Life Sciences & Healthcare Clients

--- Gordon Samson, President, Intellectual Property, Provides a Virtual Update on Strategy and Generative AI Initiatives --- LONDON , March 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today the launch of the third and final video in a series of Clarivate in the Age of AI webinar presentations led by the Presidents of its three segments: Academia & Government, Life Sciences & Healthcare and Intellectual Property.  The Intellectual Property (IP) video presentation highlights how Clarivate plays an important role in the IP ecosystem by serving as an indispensable partner to more than 20,000 customers.

New Webinar: Clarivate in the Age of AI - Driving Innovation in Intellectual Property Management and Decision Making

Clarivate PLC's 4Q23 performance disappointed investors due to a weak macrocycle, but certain parts of the business are improving. Subscription and recurring revenue growth are accelerating, comprising a significant portion of the business. Management is implementing strategies to drive organic growth, including product portfolio restructuring and a shift in the LS&H segment.

Clarivate PLC: Agree Q4'23 Was Weak, But The Upside Remains Attractive

--- Henry Levy, President, Life Sciences & Healthcare, Provides a Virtual Update on Strategy and Generative AI Initiatives --- LONDON , March 13, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today the launch of the second video in a series of Clarivate in the Age of AI webinar presentations led by the Presidents of its three segments: Academia & Government, Intellectual Property and Life Sciences & Healthcare. The Life Sciences & Healthcare video presentation highlights how Clarivate serves as an indispensable partner to our customers by providing solutions that enable mission critical decision making across the enterprise and the drug and medical device lifecycle.

New Webinar: Clarivate in the Age of AI - Empowering Our Life Sciences & Healthcare Customers to Create a Healthier Tomorrow

LONDON , March 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Jonathan Collins, Executive Vice President and Chief Financial Officer, and Henry Levy, President, Life Sciences & Healthcare, will present at the BofA Securities 2024 Information & Business Services Conference on Thursday, March 14, 2024 at 3:35 pm Eastern Time. The live webcast can be accessed at https://bofa.veracast.com/webcasts/bofa/infoservices2024/id8q5vjH.cfm and will be available for replay.

News for Clarivate Plc Stock (CLVT)